Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CCB 003

Next Previous
Drug Profile

CCB 003

Alternative Names: CCB-003

Latest Information Update: 05 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayo Clinic
  • Developer Castle Creek Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Ehlers-Danlos syndrome

Most Recent Events

  • 05 Mar 2026 Early research development is ongoing in USA (Castle Creek Pharmaceuticals pipeline, March 2026)
  • 28 Nov 2025 No recent reports of development identified for research development in Ehlers-Danlos-syndrome in USA
  • 13 Oct 2021 Mayo Clinic out-licenses CCB 003 to Castle Creek Pharmaceuticals to advance discovery and pre-clinical development in Ehlers-Danlos syndrome

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top